Patents Assigned to Mattern Pharma AG
-
Publication number: 20170189414Abstract: This invention relates to a gel formulation for nasal administration of a controlled release formulation of hormones to the systemic circulation and/or to the brain. The special lipophilic or partly lipophilic system of the invention leads to higher bioavailability of the active ingredient caused by sustained scrum levels in plasma but also leads to a more favorable serum level profile. The special lipophilic or partly lipophilic system also allows for the modulation of brain functioning. The invention also relates to the nasal administration of steroid hormones for treatment of female sexual dysfunction (FSD) or female arousal disorder.Type: ApplicationFiled: January 11, 2017Publication date: July 6, 2017Applicant: MATTERN PHARMA AGInventor: Claudia Mattern
-
Patent number: 9579280Abstract: This invention relates to a gel formulation for nasal administration of a controlled release formulation of hormones to the systemic circulation and/or to the brain. The special lipophilic or partly lipophilic system of the invention leads to higher bioavailability of the active ingredient caused by sustained serum levels in plasma but also leads to a more favorable serum level profile. The special lipophilic or partly lipophilic system also allows for the modulation of brain functioning. The invention also relates to the nasal administration of steroid hormones for treatment of female sexual dysfunction (FSD) or female arousal disorder.Type: GrantFiled: December 10, 2015Date of Patent: February 28, 2017Assignee: MATTERN PHARMA AGInventor: Claudia Mattern
-
Publication number: 20160136090Abstract: This invention relates to a gel formulation for nasal administration of a controlled release formulation of hormones to the systemic circulation and/or to the brain. The special lipophilic or partly lipophilic system of the invention leads to higher bioavailability of the active ingredient caused by sustained serum levels in plasma but also leads to a more favorable serum level profile. The special lipophilic or partly lipophilic system also allows for the modulation of brain functioning. The invention also relates to the nasal administration of steroid hormones for treatment of female sexual dysfunction (FSD) or female arousal disorder.Type: ApplicationFiled: December 10, 2015Publication date: May 19, 2016Applicant: MATTERN PHARMA AGInventor: Claudia Mattern
-
Publication number: 20160089347Abstract: This invention relates to a galenical gel formulation for nasal administration of neurotransmitters/neuromodulators such as dopamine, serotonin or pregnenolone and progesterone. The special lipophilic or partly lipophilic system of the invention leads to high bioavailability of the active ingredient in plasma and brain caused by sustained serum levels and/or direct or partly direct transport from nose to the brain.Type: ApplicationFiled: October 13, 2015Publication date: March 31, 2016Applicant: MATTERN PHARMA AGInventor: Claudia Mattern
-
Patent number: 9238072Abstract: This invention relates to a gel formulation for nasal administration of a controlled release formulation of hormones to the systemic circulation and/or to the brain. The special lipophilic or partly lipophilic system of the invention leads to higher bioavailability of the active ingredient caused by sustained serum levels in plasma but also leads to a more favorable serum level profile. The special lipophilic or partly lipophilic system also allows for the modulation of brain functioning. The invention also relates to the nasal administration of steroid hormones for treatment of female sexual dysfunction (FSD) or female arousal disorder.Type: GrantFiled: July 2, 2014Date of Patent: January 19, 2016Assignee: MATTERN PHARMA AGInventor: Claudia Mattern
-
Patent number: 9186320Abstract: This invention relates to a galenical gel formulation for nasal administration of neurotransmitters/neuromodulators such as dopamine, serotonin or pregnenolone and progesterone. The special lipophilic or partly lipophilic system of the invention leads to high bioavailability of the active ingredient in plasma and brain caused by sustained serum levels and/or direct or partly direct transport from nose to the brain.Type: GrantFiled: July 30, 2011Date of Patent: November 17, 2015Assignee: MATTERN PHARMA AGInventor: Claudia Mattern
-
Publication number: 20150005271Abstract: This invention relates to a gel formulation for nasal administration of a controlled release formulation of hormones to the systemic circulation and/or to the brain. The special lipophilic or partly lipophilic system of the invention leads to higher bioavailability of the active ingredient caused by sustained serum levels in plasma but also leads to a more favorable serum level profile. The special lipophilic or partly lipophilic system also allows for the modulation of brain functioning. The invention also relates to the nasal administration of steroid hormones for treatment of female sexual dysfunction (FSD) or female arousal disorder.Type: ApplicationFiled: July 2, 2014Publication date: January 1, 2015Applicant: MATTERN PHARMA AGInventor: Claudia Mattern
-
Patent number: 8877230Abstract: This invention relates to a pernasally administrable preparation for the controlled release of sexual hormones to the systemic circulation, in particular to a formulation which enables its active ingredient to be absorbed in a sustained manner providing a better bioavailability at very low doses and longer duration of action.Type: GrantFiled: December 10, 2011Date of Patent: November 4, 2014Assignee: Mattern Pharma AGInventor: Claudia Mattern
-
Patent number: 8784882Abstract: This invention relates to a gel formulation for nasal administration of a controlled release formulation of hormones to the systemic circulation and/or to the brain. The special lipophilic or partly lipophilic system of the invention leads to higher bioavailability of the active ingredient caused by sustained serum levels in plasma but also leads to a more favorable serum level profile. The special lipophilic or partly lipophilic system also allows for the modulation of brain functioning. The invention also relates to the nasal administration of steroid hormones for treatment of female sexual dysfunction (FSD) or female arousal disorder.Type: GrantFiled: July 29, 2011Date of Patent: July 22, 2014Assignee: Mattern Pharma AGInventor: Claudia Mattern
-
Patent number: 8784869Abstract: This invention relates to a gel formulation for nasal administration of a controlled release formulation of hormones to the systemic circulation and/or to the brain. The special lipophilic or partly lipophilic system of the invention leads to higher bioavailability of the active ingredient caused by sustained serum levels in plasma but also leads to a more favorable serum level profile. The special lipophilic or partly lipophilic system also allows for the modulation of brain functioning. The invention also relates to the nasal administration of steroid hormones for treatment of female sexual dysfunction (FSD) or female arousal disorder.Type: GrantFiled: July 12, 2012Date of Patent: July 22, 2014Assignee: Mattern Pharma AGInventor: Claudia Mattern